1. Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

2. PRIMO: Observational Study in 7924 Patients

3. Genetics: PCSK9

6. PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels

7. Dosing and Administration

8. LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline

9. Cholesterol Treatment Trialists Collaboration (N = 170,000)

10. Lipid-Lowering Goals: Back to Nature?

11. Impact of LDL-C on Plaque Progression

12. Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

13. PCSK9: Barriers

14. Large Unmet Medical Need

15. Thank you for participating in this activity
Thank you for participating in this activity. To proceed to the CME posttest, click the Earn CME Credit link on this page.